Pain Therapeutics, Inc. (NASDAQ:PTIE)

CAPS Rating: 3 out of 5

A biopharmaceutical company that develops novel drugs for pain management and oncology.

Recs

0
Player Avatar FinanceGuy58 (34.59) Submitted: 9/17/2009 9:01:03 PM : Outperform Start Price: $4.10 PTIE Score: -31.53

A virtual pharma development company with several shots on goal. Remoxy already partnered with King Pharma. Abuse resistant forms of oxycontin should be a big hit. Great royalty rates. Another pic, Durect provides the drug delivery system for one of their pipeline products. PTIE holds tons of cash too - not going away. Very lean company, they outsource almost everything.

Featured Broker Partners


Advertisement